Table 2.

Clinical trials evaluating the use of TKIs without radiotherapy in EGFRact+ NSCLC

TKI studied		Type of study	Additional treatment	N	EGFR status	ORR	iRR	OS
Erlotinib	[105]	Phase 2	Prior CT	48	8/23 EGFRact+	58.3%	NR	18.9 m
Erlotinib	[78••]	Retrospective	1) SRS + TKI 2) TKI monotherapy	50	All EGFRact+	1)88% 2)76%	NR	1) 58.4 2)19.4
Gefitinib	[105]	Phase 2	1) PriorCT+XRT 2) Prior CT	40	Chinese NS	1)36% 2)31%	38%	15 m
Gefitinib	[23••]	Phase 2	Prior CT	41	All EGFRact+	87.8%	65.80%	21.9 m
Erlotinib	[23••]	Phase 2	At progression on gefitinib	12	All EGFRact+	58.3%	NR	NR
Gefitinib	[106]	Retrospective	1) Concurrent WBRT 2) TKI monotherapy	90	12/20 EGFRact+	1) 71.4% 2)60%	1) 71% 2)40%	1) 23.4 2)14.8
Gefitinib or erlotinib	[25•]	Retrospective	Prior CT	43	All EGFRact+	72%	57%	23.6 m
Gefitinib or erlotinib	[26]	Retrospective	1) Prior XRT 2) TKI monotherapy	121	All EGFRact+	1)83.1% 2) 85.5%	1)79.7% 2)59.7%	NM but iPFS 1) 16.6 m 2) 21 m
Gefitinib or erlotinib	[45]	Phase 2	Prior CT	28	All EGFRact+	83%	83%	15.9 m
Gefitinib or erlotinib	[95]	Retrospective	1) TKI + XRT 2) TKI monotherapy	89	All EGFRact+	NR	NR	1) 26 m 2) 21.5 m
Gefitinib or erlotinib	[107]	Retrospective	1) WBRT + TKI 2) TKI monotherapy	81	All EGFRact+	NR	NR	1) 18.5 m 2) 17 m
Gefitinib or erlotinib	[96]	Retrospective	1) SRS+ TKI 2) TKI monotherapy and salvage XRT	162	All EGFRact+	NR	NR	1) 40.8 m 2) 20.5 m

CT chemotherapy, EGFRact+ epidermal growth factor activating mutation, m months, iPFS intracranial progression free survival, iRR intracranial response rate, NM data not matured, NS not screened for EGFRact+, NR not reported, PFS progression free survival, ORR overall response rate, OS overall survival, RR response rate, TKI tyrosine kinase inhibitor, XRT radiotherapy